Skip to main content

Share story

Science

Scientists discover a hidden gut bacterium linked to good health

Scientists discover a hidden gut bacterium linked to good health Image: Primary
Researchers at the University of Cambridge led a large international study that identified a group of gut bacteria called CAG-170. The bacteria appear at higher levels in healthy people and at lower levels in individuals with chronic conditions including inflammatory bowel disease, obesity, and chronic fatigue syndrome. The team examined gut microbiome samples from more than 11,000 people in 39 countries. CAG-170 is identified only by its genetic signature, as most of the bacteria have not been grown in laboratory conditions. Genetic analysis showed the bacteria produce large amounts of vitamin B12 and enzymes that break down carbohydrates, sugars, and fibers in the gut. Researchers believe the vitamin B12 supports other beneficial bacteria and helps maintain the overall gut ecosystem. The findings indicate that CAG-170 could serve as a marker for gut microbiome health. The study also suggests potential for developing probiotics to support healthy levels of the bacteria. Dr. Alexandre Almeida of the University of Cambridge Department of Veterinary Medicine led the research, which was published in the journal Cell Host and Microbe.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from ScienceDaily and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.